Overview

Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors

Status:
Completed

Trial end date:
2010-01-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiofrequency ablation uses high-frequency electric current to kill tumor cells. Combining radiofrequency ablation with liposomal doxorubicin may increase the effectiveness of the drug and kill more tumor cells. PURPOSE: This phase I trial is studying the best dose of liposomal doxorubicin when given with radiofrequency ablation in treating patients with primary or metastatic liver tumors.

Phase:

Phase 1

Details

Lead Sponsor:

National Institutes of Health Clinical Center (CC)

Collaborator:

National Cancer Institute (NCI)

Treatments:

Doxorubicin
Liposomal doxorubicin